Blautix (CJRB-205) / 4D Pharma, CJ Biosci - LARVOL DELTA

Drugs of the future for diarrhea-predominant irritable bowel syndrome: an overview of current investigational drugs. (PubMed, Expert Opin Investig Drugs) - "Clinical trial evidence has shown that loperamide, eluxadoline, alosetron, ramosetron, bile acid sequestrants, and rifaximin can modulate GI alterations and benefit patients with IBS-D. Among the potential therapies, ibodutant, ibudilast, blautix, BOS-589, solabegron, vibegron, olorinab, ebastine, and ORP-101 have demonstrated possible effects but remain confirmed...Therefore, we should focus on developing new, efficient, and affordable medications for IBS-D. The government, insurers, and society must recognize this need and collaborate to ensure its fulfillment."

Journal • Review • Gastrointestinal Disorder • Inflammation

IMPACTS OF THE ADMINISTRATION OF BLAUTIX®, A THERAPEUTICALLY ACTIVE STRAIN OF BLAUTIA HYDROGENOTROPHICA, ON GUT MICROBIOTA STRUCTURE IN IRRITABLE BOWEL SYNDROME (IBS) (DDW 2023) - P2 | "Blautix is a safe and promising therapeutic option for treatment of IBS, irrespective of clinical subtype. The predicted functional and observed structural changes in gut microbiota after Blautix administration represent new mechanistic pathways through which Blautix can alleviate IBS symptomology."

Gut Microbiota • Gastrointestinal Disorder

"Your org should buy the rights to Blautix since it's up for grabs now. The bacteria feeds on hydrogen." (@KenTakata6)

Randomised clinical trial: efficacy and safety of the live biotherapeutic product MRx1234 in patients with irritable bowel syndrome. (PubMed, Aliment Pharmacol Ther) - P2 | "MRx1234 has the potential to become a novel, safe treatment option for patients with IBS-C or IBS-D, and for those who have mixed symptoms or transition between subtypes."

Journal • Constipation • Gastroenterology • Gastrointestinal Disorder • Immunology • Pain

[VIRTUAL] A PHASE II STUDY OF LIVE BIOTHERAPEUTIC BLAUTIX IN IRRITABLE BOWEL SYNDROME (IBS) PATIENTS WITH SUBTYPES IBS-D AND IBS-D (DDW 2021) - "Across Blautix and placebo treatment groups respectively, 32.8% and 33.0% pts experienced AE(s).ConclusionsSingle strain Live Biotherapeutic Blautix demonstrated activity in both IBS-C and IBS-D, including a particularly strong effect on bowel habit, and excellent safety profile. Further analyses ongoing to support Phase III pivotal trial design."

Clinical • P2 data • Constipation • Gastrointestinal Disorder • Immunology • Pain

"Blautix, the new Biotherapeutic treatment for #IBS 4DPharma at #DDW2021 #DDDD, #LBPS" (@Madtweete)